Skip to main page content

. 1999 Sep;23(1):18-20.

doi: 10.1038/12615.

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas

D Cappellen¹, C De Oliveira, D Ricol, S de Medina, J Bourdin, X Sastre-Garau, D Chopin, J P Thiery, F Radvanyi

Affiliations

Affiliation

¹ Laboratoire de Morphogenèse Cellulaire et Progression Tumorale, UMR 144, Centre National de la Recherche Scientifique, Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France.

PMID: 10471491
DOI: 10.1038/12615

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas

D Cappellen et al. Nat Genet. 1999 Sep.

. 1999 Sep;23(1):18-20.

doi: 10.1038/12615.

Authors

D Cappellen¹, C De Oliveira, D Ricol, S de Medina, J Bourdin, X Sastre-Garau, D Chopin, J P Thiery, F Radvanyi

Affiliation

¹ Laboratoire de Morphogenèse Cellulaire et Progression Tumorale, UMR 144, Centre National de la Recherche Scientifique, Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Paris Cedex 05, France.

PMID: 10471491
DOI: 10.1038/12615

No abstract available

PubMed Disclaimer

Similar articles

Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.
Wu R, Connolly D, Ngelangel C, Bosch FX, Muñoz N, Cho KR. Wu R, et al. Oncogene. 2000 Nov 16;19(48):5543-6. doi: 10.1038/sj.onc.1203934. Oncogene. 2000. PMID: 11114733
Absence of FGFR3 mutations in urinary bladder tumours of rats and mice treated with N-butyl-N-(-4-hydroxybutyl)nitrosamine.
Dunois-Lardé C, Levrel O, Brams A, Thiery JP, Radvanyi F. Dunois-Lardé C, et al. Mol Carcinog. 2005 Mar;42(3):142-9. doi: 10.1002/mc.20075. Mol Carcinog. 2005. PMID: 15690367
Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ, Saenz P, Molina M, Cuevas González J, Escuredo K, Santa Cruz S, Junquera C, Simón L, Martínez A, Gutiérrez Baños JL, López-Brea M, Esparza C, Val-Bernal JF. Gómez-Román JJ, et al. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):459-65. Clin Cancer Res. 2005. PMID: 15701828
The role of mutations and overexpression of the fibroblast growth factor receptor-3 in bladder cancer.
Wang QY, Zhao Y, Zhang R. Wang QY, et al. Minerva Med. 2015 Dec;106(6):333-7. Epub 2015 Nov 5. Minerva Med. 2015. PMID: 26542242 Review.
Hypochondroplasia: molecular analysis of the fibroblast growth factor receptor 3 gene.
Bellus GA, McIntosh I, Szabo J, Aylsworth A, Kaitila I, Francomano CA. Bellus GA, et al. Ann N Y Acad Sci. 1996 Jun 8;785:182-7. doi: 10.1111/j.1749-6632.1996.tb56257.x. Ann N Y Acad Sci. 1996. PMID: 8702125 Review. No abstract available.

See all similar articles

Cited by

The KLF16/MYC feedback loop is a therapeutic target in bladder cancer.
Zheng L, Wang J, Han S, Zhong L, Liu Z, Li B, Zhang R, Zhou L, Zheng X, Liu Z, Zeng C, Li R, Zou Y, Wang L, Wu Y, Kang T. Zheng L, et al. J Exp Clin Cancer Res. 2024 Nov 18;43(1):303. doi: 10.1186/s13046-024-03224-3. J Exp Clin Cancer Res. 2024. PMID: 39551759 Free PMC article.
Strategies to Improve Clinical Outcomes and Patient Experience Undergoing Transurethral Resection of Bladder Tumor.
Sepehri S, Rezaee ME, Su ZT, Kates M. Sepehri S, et al. Curr Urol Rep. 2024 Oct 11;26(1):13. doi: 10.1007/s11934-024-01243-3. Curr Urol Rep. 2024. PMID: 39390270 Review.
FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.
Noeraparast M, Krajina K, Pichler R, Niedersüß-Beke D, Shariat SF, Grünwald V, Ahyai S, Pichler M. Noeraparast M, et al. Cancer Commun (Lond). 2024 Oct;44(10):1189-1208. doi: 10.1002/cac2.12602. Epub 2024 Aug 19. Cancer Commun (Lond). 2024. PMID: 39161208 Free PMC article. Review.
A Tetravalent Bispecific Antibody Selectively Inhibits Diverse FGFR3 Oncogenic Variants.
Yang Y, Suhasini AN, Jiang Z, Liu N, Rosconi M, Zhang B, Li Y, Dudgeon D, Seong C, Kim S, Rafique A, Huang T, Bhosle S, Krueger P, Ullman E, Olson W, Lin JC, Shen Y, Daly C. Yang Y, et al. Cancer Res. 2024 Jul 2;84(13):2169-2180. doi: 10.1158/0008-5472.CAN-23-3195. Cancer Res. 2024. PMID: 39082679 Free PMC article.
Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, Tian X, Guan X, Cen X, Zhao Y. Zhou Y, et al. Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2. Signal Transduct Target Ther. 2024. PMID: 38763973 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information
Molecular Biology Databases
- GlyGen glycoinformatics resource
- The Weizmann Institute of Science GeneCards and MalaCards databases